Author: seva@padda.com

  • The Sugar That Caramelizes Your Nerves: How Glucose Damages Your Nervous System

    The same chemistry that browns a steak in a hot pan and gives bread its crust is happening, slowly and silently, inside the body of anyone with chronically elevated blood sugar. It is called the Maillard reaction, and when it plays out on the proteins of your nervous system, the result is stiffened, short-circuited, and eventually dying nerves. This article explains — in plain terms but with real biochemistry — how glucose damages nerves through glycation, why it produces the burning feet of diabetic neuropathy, and why a single fasting glucose test can miss the process entirely.

    The Maillard reaction: caramelizing from the inside

    In 1912, the French chemist Louis-Camille Maillard described what happens when sugars react with proteins: they bond together and form new, brown, rigid compounds. In cooking, that reaction creates flavor and color. In the body, the same reaction runs on your own tissues whenever glucose is abundant. Glucose molecules latch onto proteins — including the structural and functional proteins of nerves — and, through a series of steps, form stable end-products.

    These are called Advanced Glycation End-products, or AGEs — an apt acronym, because the process is a form of accelerated aging of the tissue. Once formed, AGEs are hard to remove, and they accumulate over years of elevated blood sugar.

    Three ways AGEs injure nerves

    Glycation harms nerves through several converging mechanisms.

    1. Structural cross-linking. AGEs bind proteins to one another, cross-linking them into stiff, dysfunctional complexes. In a nerve, this degrades the delicate architecture required to conduct signals and to maintain the insulating myelin sheath. Cross-linked proteins in the walls of the tiny blood vessels feeding the nerve also stiffen those vessels, choking the nerve’s blood supply.

    2. Inflammatory ignition through RAGE. AGEs are not just inert debris. They bind to a specific receptor called RAGE (the receptor for advanced glycation end-products) on the surface of cells. Activating RAGE switches on inflammatory signaling cascades, flooding the tissue with inflammatory mediators and oxidative stress. The nerve is effectively set on a low, chronic inflammatory fire.

    3. Oxidative stress and the polyol pathway. When glucose is abundant, some of it is shunted through the polyol pathway, where the enzyme aldose reductase converts glucose to sorbitol. This process consumes NADPH — the same molecule the cell needs to regenerate glutathione, its master antioxidant. The nerve is thus hit twice: sorbitol accumulates and draws water into the cell, while the antioxidant defense is depleted just as oxidative stress is rising.

    The unifying mechanism: mitochondrial overload

    How do these pathways connect? The landmark work of Dr. Michael Brownlee, published in Nature in 2001, proposed a unifying explanation: excess glucose overloads the mitochondria — the cell’s power plants — causing them to overproduce a damaging molecule called superoxide. That single upstream event, Brownlee argued, switches on the glycation, polyol, and inflammatory pathways together. In other words, mitochondrial overload is the common root, and AGEs, sorbitol accumulation, and RAGE-driven inflammation are its branches. This is why effective treatment has to consider mitochondrial health, not just blood sugar numbers in isolation.

    Why the feet burn first

    Nerves signal by maintaining a precise electrical and chemical environment along their length. As glycation stiffens their structure, inflammation irritates them, and oxidative stress and poor blood flow starve them of energy, the fibers begin to misfire — generating the burning, tingling, and electric sensations of neuropathy — and then to die back. Because the process is length-dependent, the longest nerves, which reach the feet, are affected first. That is the biochemical reason diabetic neuropathy characteristically begins in the toes and moves upward.

    Beyond the feet: the brain connection

    The reach of glucose-driven damage does not stop at the peripheral nerves. Research by Dr. Suzanne de la Monte at Brown University introduced the concept of Alzheimer’s disease as, in part, a metabolic disorder of brain insulin signaling — sometimes called “type 3 diabetes.” The same terrain of glycation, inflammation, and insulin resistance that injures peripheral nerves also appears to affect the brain, which is one reason chronic high blood sugar is associated with cognitive symptoms as well as neuropathy.

    Why a single glucose test isn’t enough

    A one-time fasting glucose is a snapshot; glycation is a movie. Because AGE formation depends on cumulative sugar exposure over time, better windows into the process include HbA1c (which reflects average glucose over roughly three months and is itself a glycated protein), a glucose tolerance test (which can reveal impaired glucose handling that fasting numbers miss), and markers of the downstream damage. Catching dysregulation at the prediabetes stage — before a formal diabetes diagnosis — matters, because nerve damage can begin there.

    What this means for treatment

    The biochemistry points directly at the strategy: reduce the ongoing glucose exposure driving glycation, support the antioxidant defenses (glutathione and its cofactors) that the polyol pathway depletes, and restore mitochondrial function so the upstream overload eases. This is the rationale behind a terrain-focused approach that pairs glycemic control with targeted metabolic and mitochondrial support, rather than relying only on drugs that mask the resulting pain.

    Frequently asked questions

    Can nerve damage from high blood sugar be undone?

    Some can, especially when caught early and when the underlying glucose exposure and oxidative stress are corrected. Established damage may only partly recover, so the priority becomes halting progression. Individual results vary.

    My fasting glucose is normal — am I in the clear?

    Not necessarily. HbA1c and a glucose tolerance test reveal patterns a single fasting number misses, and nerve damage can begin at the prediabetes stage.

    What are AGEs, in one sentence?

    Advanced glycation end-products are stiff, damaging compounds formed when sugar bonds to your proteins — the body’s internal version of caramelization.

    Does this affect anything besides my feet?

    Yes. The same metabolic terrain is linked to blood-vessel disease and to cognitive effects; research describes an insulin-resistance component of brain disease sometimes called “type 3 diabetes.”

    Key takeaways

    • The Maillard reaction bonds glucose to your proteins, forming stiff, damaging AGEs.
    • AGEs harm nerves by cross-linking structure, activating RAGE-driven inflammation, and driving oxidative stress via the polyol pathway.
    • Brownlee’s work identifies mitochondrial overload as the unifying upstream event.
    • Damage is length-dependent, so the feet are affected first.
    • HbA1c and glucose tolerance testing reveal the process better than a single fasting glucose.

    Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

    This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902.

    References

    1. Maillard LC. Action des acides aminés sur les sucres; formation des mélanoïdines par voie méthodique. C R Acad Sci. 1912;154:66–68.
    2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
    3. Vlassara H, Uribarri J. Advanced glycation end products (AGEs) and diabetes. Curr Diab Rep. 2014.
    4. de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes—evidence reviewed. J Diabetes Sci Technol. 2008;2(6):1101–1113.
    5. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol. 2002.

    Find out what is driving your nerve pain

    The free, five-question Nerve Damage Score takes about two minutes and tells you which terrain failure is most likely behind your symptoms.

    Get My Free Nerve Damage Score

    Or call or text (314) 886-5902.

    Related reading

  • Is Your Diet Destroying Your Nerves? The Gluten–Neuropathy Connection

    Most people think of gluten as a digestive issue — a problem for the gut, felt as bloating or diarrhea. But some of the most important consequences of gluten sensitivity are neurological, and they can appear in people whose intestines seem perfectly fine. Gluten can injure the nervous system directly, producing peripheral neuropathy and balance problems even in the complete absence of celiac disease. This article explains the immune mechanism behind that, why standard celiac testing so often misses it, and what the evidence says about dietary elimination.

    Gluten sensitivity is not only celiac disease

    Celiac disease is an autoimmune reaction to gluten that damages the small intestine. But researchers — most prominently Dr. Marios Hadjivassiliou and colleagues in Sheffield, UK — have spent decades documenting a broader category of gluten-related disorders in which the primary target is not the gut but the nervous system. In many of these patients, intestinal biopsy is normal or near-normal, and yet the neurological damage is real and progressive.

    This matters enormously, because a patient with gluten neuropathy who is told “your celiac test is negative, so gluten isn’t your problem” may continue eating the very trigger that is dismantling their nerves.

    Molecular mimicry: how the immune system confuses nerves for gluten

    The central mechanism is molecular mimicry. When the immune system mounts a response to gluten, it produces antibodies. In susceptible people, some of those antibodies cross-react with the body’s own tissues because a molecular structure in nervous tissue resembles the gluten fragment closely enough to be mistaken for it.

    A key player is an enzyme family called transglutaminase. In celiac disease, the immune attack targets transglutaminase-2, concentrated in the gut. In gluten-related neurological disease, antibodies against transglutaminase-6 (TG6) — an isoform expressed in the nervous system — have been identified as a marker of the neural attack. Antibodies can also target the myelin that insulates nerves. The result is an immune assault on the peripheral nerves (neuropathy) and, in some patients, on the cerebellum, producing gluten ataxia — a loss of coordination and balance.

    What gluten neuropathy feels like

    Gluten neuropathy most often presents as a length-dependent sensory neuropathy: tingling, numbness, and burning that begin in the feet. Because it develops slowly and can occur without digestive symptoms, it is frequently mislabeled as idiopathic. When the cerebellum is involved, patients may notice unsteadiness, a wide-based gait, or clumsiness that they attribute to aging. The combination of an unexplained sensory neuropathy and subtle balance problems should raise the question of gluten sensitivity.

    Why the celiac test misses it

    Standard celiac screening looks for the intestinal form of the disease — typically tissue transglutaminase-2 (tTG) antibodies and evidence of gut damage. It is not designed to detect the neurological form. A patient can have a completely negative celiac panel and still be producing the TG6 and anti-myelin antibodies driving nerve injury. This is why a negative celiac test does not rule out gluten as a cause of neuropathy — a point explored further in the companion article on negative celiac testing.

    Genetic testing (for the HLA-DQ2/DQ8 haplotypes that predispose to gluten sensitivity) and expanded antibody panels give a more complete picture than a routine celiac screen alone.

    The role of strict elimination

    Because the damage is driven by an ongoing immune response to gluten, the logical — and evidence-supported — intervention is strict, sustained gluten elimination. Hadjivassiliou’s group has reported that patients who adhere rigorously to a gluten-free diet can see stabilization and, in some cases, improvement of their neurological symptoms, while partial or inconsistent avoidance is often insufficient. Nerve tissue recovers slowly, so improvement, when it comes, unfolds over months, and the earlier the trigger is removed, the more function there is to preserve.

    “Strict” is the operative word. Unlike a lifestyle preference, therapeutic gluten elimination for neurological disease means eliminating cross-contamination and hidden sources — not simply cutting back on bread. This is best done with dietary guidance and monitoring.

    Where this fits in a root-cause evaluation

    Gluten is one driver among several that can masquerade as idiopathic neuropathy. In a thorough workup it is evaluated alongside metabolic, toxic, and mechanical contributors, because more than one can be present at once. The value of identifying a gluten contribution is that it is, in principle, entirely removable — the trigger is on the plate.

    Frequently asked questions

    Can I have gluten neuropathy if my celiac test is negative?

    Yes. Standard celiac tests detect the intestinal form of gluten disease, not the neurological form. TG6 and anti-myelin antibodies can be present with a negative celiac panel.

    Do I need digestive symptoms to have gluten neuropathy?

    No. Many patients with gluten-related nerve damage have no significant gut symptoms at all.

    Will going gluten-free fix my neuropathy?

    It can help stabilize and sometimes improve symptoms when done strictly and early, but nerve recovery is slow and varies by individual. It is most effective as part of a physician-guided plan.

    How strict do I need to be?

    For neurological gluten disease, strict elimination — including hidden and cross-contaminating sources — appears necessary; occasional avoidance is generally not enough.

    Key takeaways

    • Gluten can injure nerves and the cerebellum directly, independent of celiac disease.
    • The mechanism is immune molecular mimicry, with transglutaminase-6 antibodies marking the neural attack.
    • Standard celiac tests do not detect the neurological form; a negative result does not clear gluten.
    • Strict, sustained gluten elimination is the evidence-supported intervention, with slow, partial recovery possible.
    • Gluten is evaluated alongside other neuropathy drivers, and is uniquely removable.

    Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

    This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not make major dietary or medication changes without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902.

    References

    1. Hadjivassiliou M, Grünewald RA, Davies-Jones GAB. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry. 2002;72:560–563.
    2. Hadjivassiliou M, et al. Transglutaminase-6 antibodies in the diagnosis of gluten ataxia. Neurology. 2013;80:1740–1745.
    3. Hadjivassiliou M, et al. Gluten neuropathy. Muscle Nerve / Brain (peripheral neuropathy series).
    4. Hadjivassiliou M, et al. Neurologic deficits in patients with gluten sensitivity — role of strict gluten-free diet.

    Note: match each reference to the specific paper at publication; the Sheffield group has an extensive body of work in this area.

    Find out what is driving your nerve pain

    The free, five-question Nerve Damage Score takes about two minutes and tells you which terrain failure is most likely behind your symptoms.

    Get My Free Nerve Damage Score

    Or call or text (314) 886-5902.

    Related reading

  • The Neuropathy Breakthrough Mainstream Medicine Overlooked: The High-Concentration Capsaicin Protocol

    There is a treatment for neuropathic foot pain that is FDA-approved, non-opioid, non-systemic, and applied in a doctor’s office in under an hour — and yet many patients living with burning feet have never been offered it. It is the high-concentration 8% capsaicin patch. This article explains how it works, what the clinical evidence genuinely shows, why it often takes more than one treatment to see the full benefit, and how it fits into a repair-focused protocol. It also draws a careful line between what is proven and what is still being studied — because that distinction is exactly what “mainstream medicine missed” conversations tend to blur.

    A note on numbers, up front

    You may have seen a very high success figure attached to this protocol. In the interest of honesty: the controlled clinical trials of the 8% capsaicin patch show modest but statistically significant pain relief, not near-universal cure. Any higher real-world success rate reported by an individual clinic reflects that clinic’s own patient population, protocol, and outcome definition — it is a practice observation, not a figure from the randomized trials, and it should be understood that way. What follows sticks to the published science, then explains where clinical experience extends beyond it.

    The receptor that makes chili peppers hot

    Capsaicin is the compound that gives chili peppers their heat. It acts on a specific sensor on pain-sensing nerve endings called the TRPV1 receptor (transient receptor potential vanilloid 1). TRPV1 is the same receptor that responds to noxious heat — which is why capsaicin literally feels hot.

    Low-dose capsaicin creams (0.025–0.075%) available over the counter provide mild, temporary relief and must be applied several times a day. The prescription 8% patch is a different order of magnitude — roughly a hundredfold more concentrated — and is designed to do something the creams cannot: temporarily defunctionalize the overactive pain fibers.

    Defunctionalization: turning down an alarm that won’t stop

    In chronic neuropathy, the small C-fibers in the skin become pathologically hyperexcitable. They fire pain signals continuously, even without a real stimulus — the alarm is stuck on. A single, controlled 30-minute application of the 8% patch delivers enough capsaicin to overstimulate those TRPV1-bearing endings and then reversibly quiet them. The nerve endings retract and stop transmitting their runaway pain signals; over the following weeks and months they gradually recover. Crucially, controlled studies found this happens without degrading normal sensation — patients retained their ability to feel sharp, warm, cold, and vibration stimuli.

    Because the treatment is topical and non-systemic, it sidesteps the sedation, dizziness, and cognitive fog that limit oral neuropathic-pain drugs. The main side effect is temporary burning and redness at the application site, which is why the patch is applied in a clinical setting, often with skin pre-treatment for comfort.

    What the evidence shows

    The 8% patch first earned FDA approval in 2009 for postherpetic neuralgia (the lingering nerve pain after shingles). In 2020, on the strength of the pivotal STEP trial led by Dr. David Simpson, the FDA extended approval to painful diabetic peripheral neuropathy of the feet. In STEP, a single 30-minute treatment produced a statistically significant reduction in average daily pain compared with placebo. A separate 52-week study (PACE) confirmed that repeated treatments were well tolerated over a full year, with no worsening of sensory function.

    This is the honest headline: the patch reliably and safely reduces pain for a meaningful share of patients, and it can be repeated approximately every three months.

    Why persistence matters

    One reason patients — and sometimes physicians — give up too soon is that they expect a single patch to do everything. The data and clinical experience both suggest the benefit often builds across successive cycles. Each treatment quiets the overfiring fibers again and extends the window of reduced pain. For a chronic condition that took years to develop, expecting resolution from one application is unrealistic; the protocol is designed around repeated, spaced treatments.

    The investigational frontier: can it help nerves regrow?

    Here is where the science is genuinely exciting but not yet settled. Because capsaicin causes nerve endings to retract and then regenerate, researchers have asked whether repeated treatment might not just relieve pain but actually encourage healthier re-innervation of the skin — in other words, whether it could be disease-modifying. A randomized trial in the United Kingdom is formally testing exactly this question in diabetic neuropathy.

    Until that kind of study reports, the responsible position is: the 8% patch is proven for pain relief, and its potential to modify the underlying nerve damage is a promising hypothesis under active investigation. Regenerve’s approach uses the pain-relief window the patch creates as the foundation for the repair-focused steps — orthobiologics and mitochondrial and metabolic support — that aim at the nerve itself. Those regenerative components, as covered in the protocol article, are themselves emerging and individualized rather than guaranteed.

    Who is a candidate

    The patch is used for localized neuropathic pain, classically in the feet for diabetic neuropathy and in the affected area for postherpetic neuralgia. Suitability depends on a physician’s evaluation of the pain distribution, skin integrity, and overall picture. As with any treatment, it works best as part of a plan that also addresses the root drivers of the neuropathy rather than as a standalone fix.

    Frequently asked questions

    Does the capsaicin patch cure neuropathy?

    No. It reduces neuropathic pain — often meaningfully and safely — and can be repeated. It is not a cure, and its ability to reverse nerve damage is still under investigation.

    How is it different from capsaicin cream?

    The 8% patch is prescription-strength, applied once in a clinical setting for about 30 minutes, and roughly 100 times more concentrated than over-the-counter creams.

    Does it hurt?

    There is temporary burning and redness at the site during and shortly after application. It is applied under supervision, often with steps taken to improve comfort, and does not damage normal sensation.

    How often can it be repeated?

    Approximately every three months, and benefit often accumulates over successive treatments.

    What about that very high success rate I saw?

    Controlled trials show modest, significant relief. Higher figures reported by a clinic reflect its own real-world experience and outcome definitions, not the randomized-trial data, and should be interpreted with that context.

    Key takeaways

    • The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet (2020) and postherpetic neuralgia (2009).
    • It works by reversibly quieting overfiring TRPV1 pain fibers, without degrading normal sensation, and without systemic side effects.
    • Trial evidence supports real but modest pain relief; benefit often builds across repeated treatments.
    • Whether it can help nerves regenerate is a legitimate, still-unproven hypothesis under study.
    • It works best inside a plan that also treats the neuropathy’s root causes.

    Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

    This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any treatment without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902.

    References

    1. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
    2. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for painful diabetic peripheral neuropathy of the feet. 2020; original PHN approval 2009.
    3. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
    4. Anand P, Bley K. Topical capsaicin for pain management: mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
    5. Abrams RMC, et al. A critical review of the capsaicin 8% patch for diabetic peripheral neuropathy of the feet. Expert Rev Neurother. 2021.

    Find out what is driving your nerve pain

    The free, five-question Nerve Damage Score takes about two minutes and tells you which terrain failure is most likely behind your symptoms.

    Get My Free Nerve Damage Score

    Or call or text (314) 886-5902.

    Related reading

  • Peripheral Neuropathy: The 11 Hidden Drivers Your Doctor Missed

    When a workup comes back inconclusive, many patients are told their neuropathy is “idiopathic” — medical language for cause unknown. But in a large share of these cases, the cause isn’t truly unknown; it simply hasn’t been looked for thoroughly enough. Idiopathic is too often a clinical surrender rather than a diagnosis. This article lays out the systematic investigation Dr. Padda uses to hunt down the real driver of nerve damage, organized into three domains — metabolic, toxic, and mechanical — because a nerve can die from many directions, and finding which one is the difference between managing symptoms forever and actually changing course.

    “Idiopathic” is often incomplete, not unsolvable

    Studies of unexplained peripheral neuropathy consistently show that when patients undergo a structured, expanded evaluation, an identifiable cause emerges in a substantial proportion of cases previously labeled idiopathic. The American Academy of Neurology’s evaluation guidance for distal symmetric polyneuropathy emphasizes a tiered laboratory workup precisely because targeted testing changes management. The point is not that every case has an easy answer — some remain genuinely unexplained — but that the label should be earned only after a real search.

    The three-domain framework below is a way to organize that search so nothing obvious gets skipped.

    Domain one: metabolic drivers

    Metabolic problems are the most common and most treatable causes of nerve damage. They share a final common pathway — energy failure and chemical injury inside the nerve.

    1. Blood sugar and glycation. Diabetes is the leading cause of neuropathy worldwide, but the damage begins earlier than most people realize. Research from the University of Utah (Drs. Smith and Singleton) helped establish that even prediabetes — impaired glucose tolerance that never reaches the diabetes threshold — is associated with small-fiber neuropathy. Chronically elevated glucose bonds to nerve proteins to form advanced glycation end-products through the Maillard reaction, first described by Louis-Camille Maillard in 1912. A standard fasting glucose can miss this entirely; markers like HbA1c and a glucose tolerance test reveal far more. (Explored in depth in the glycation and blood-sugar articles.)

    2. Intracellular nutritional deficiency. Nerves are cofactor-hungry. Deficiencies of B1 (thiamine), B6, B12, folate, magnesium, and omega-3 fatty acids each impair nerve function and mitochondrial energy production. Crucially, blood levels can look “normal” while the tissue is starved — which is why functional testing matters (see driver 3).

    3. Functional B12 deficiency. A serum B12 in the normal range does not rule out a cellular deficiency. Functional markers — methylmalonic acid (MMA) and homocysteine — rise when B12 is functionally inadequate at the tissue level, catching deficiencies a standard B12 test misses. Untreated, B12 deficiency causes a characteristic neuropathy (and can damage the spinal cord), yet it is eminently correctable. (Covered fully in the B12 article.)

    Domain two: toxic drivers

    If metabolic drivers are about deprivation, toxic drivers are about poisoning — substances that damage nerves directly or by depleting the body’s defenses.

    4. Bioaccumulated heavy metals. Lead, arsenic, mercury, and thallium disrupt essential enzymes and deplete glutathione, the body’s master antioxidant. Exposure is often occupational or environmental and accumulates silently over years. Testing should be guided by a genuine exposure history — and, importantly, patients should be steered away from unproven or aggressive “detox” schemes, which can do more harm than good. (See the heavy-metals article.)

    5. Mold and mycotoxins. Toxins produced by mold in water-damaged buildings can impair mitochondrial function and drive neuroinflammation, sometimes presenting as neuropathy paired with profound fatigue. This is a genuinely debated clinical area, and it deserves careful, evidence-aware evaluation rather than either dismissal or overdiagnosis. (See the mycotoxin article.)

    6. Neurotoxic medications. Some of the most commonly prescribed drugs can quietly undermine nerve health. Statins can deplete CoQ10; metformin — one of the most-prescribed diabetes drugs — can cause B12 deficiency over time; certain chemotherapy agents and antibiotics are directly neurotoxic. The answer is rarely to stop a needed medication, but to monitor and replete the nutrients they affect. (See the statins-and-metformin article.)

    7. Alcohol. Alcohol is a double hit: acetaldehyde and alcohol itself are directly toxic to nerves, and heavy use depletes thiamine and other B vitamins. Recovery depends on reducing exposure and repleting nutrients — but abrupt cessation in someone alcohol-dependent carries its own medical risks and should be handled with clinical guidance. (See the alcohol article.)

    Domain three: mechanical and immune drivers

    The final domain covers physical and immune-mediated injury — nerves crushed, choked, or caught in the crossfire of the body’s own defenses.

    8. Autoimmune disease. Conditions like lupus, rheumatoid arthritis, and Sjögren’s damage nerves through vasculitis (inflammation of the small vessels feeding the nerve) and direct antibody attack. Here the neuropathy is collateral damage from a systemic process, so treatment requires controlling the underlying disease and addressing the nerve. (See the autoimmune article.)

    9. Gluten sensitivity. Even without celiac disease, gluten can trigger a neurological immune response — antibodies against transglutaminase-6 have been linked to neuropathy and cerebellar ataxia in work led by Dr. Marios Hadjivassiliou. A negative celiac test does not rule this out. (See the two gluten articles.)

    10. Chronic stealth infections. Certain infections hide in nervous tissue. The varicella-zoster (shingles) virus resides in the dorsal root ganglia and can reactivate to cause postherpetic neuralgia; Lyme and other pathogens can also produce neuropathy. (See the shingles article.)

    11. Mechanical compression. Sometimes it isn’t a metabolic disease at all — it’s a pinched nerve. Carpal tunnel syndrome, radiculopathy (sciatica), and other entrapments injure nerves through ischemia and focal demyelination. The concept of double crush syndrome, described by Upton and McComas in 1973, explains why a metabolically stressed nerve is more vulnerable to a second, mechanical injury — meaning compression and metabolic disease often compound each other. (See the compression article.)

    Why one patient often has several drivers at once

    These categories are not mutually exclusive. A person with prediabetes, a statin prescription, and a compressed nerve at the wrist may have three simultaneous drivers, each amplifying the others. This is the practical reason a single-cause mindset fails: the workup has to be broad enough to catch combinations, and the treatment plan has to address all the active contributors, not just the most obvious one.

    What a thorough workup looks like

    A genuine root-cause investigation typically includes a detailed history (occupation, exposures, diet, alcohol, medications, family history), an expanded metabolic panel (glucose tolerance and HbA1c, not just fasting glucose), functional nutrient testing (MMA and homocysteine, thiamine, magnesium), targeted autoimmune and infectious testing when the history points that way, and — where relevant — nerve conduction studies or skin biopsy to characterize the fiber types involved. The aim is to convert “idiopathic” into a named, addressable cause whenever the evidence allows.

    Frequently asked questions

    My tests were normal — does that mean there’s no cause?

    Not necessarily. Standard panels can miss functional deficiencies (like tissue-level B12), early glucose dysregulation, and toxic exposures. A broader, targeted workup often uncovers a driver that routine testing skips.

    Can more than one thing be causing my neuropathy?

    Yes, and it’s common. Multiple drivers frequently coexist and compound one another, which is why a complete evaluation matters.

    Is it too late if I’ve had neuropathy for years?

    Identifying and removing an active driver can slow or halt progression at any stage, and some function may recover. Earlier is better, but a workup is worthwhile regardless of how long symptoms have been present.

    Should I try a detox for heavy metals?

    Only under medical guidance and only if testing and history justify it. Unproven chelation and “detox” protocols carry real risks and should not be self-administered.

    Key takeaways

    • “Idiopathic” often means the search was incomplete, not that no cause exists.
    • Nerve damage arises from metabolic, toxic, and mechanical drivers — often several at once.
    • Standard labs miss a lot: functional B12 markers, glucose tolerance, and exposure-guided testing reveal more.
    • Double crush syndrome shows how metabolic and mechanical injuries compound each other.
    • The goal of the workup is to convert an unexplained neuropathy into a named, treatable one.

    Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

    This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication or treatment without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902 to begin a root-cause evaluation.

    References

    1. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research (AAN/AANEM/AAPM&R). Neurology. 2005; and the AAN evaluation guidance, Neurology. 2009.
    2. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist / Diabetes Care (University of Utah body of work).
    3. Maillard LC. Action des acides aminés sur les sucres. C R Acad Sci. 1912.
    4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
    5. Hadjivassiliou M, et al. Transglutaminase-6 antibodies and gluten-related neurological dysfunction. Neurology / Ann Neurol.
    6. Upton ARM, McComas AJ. The double crush in nerve-entrapment syndromes. Lancet. 1973;2(7825):359–362.

    Note: match each reference to a specific, current source at publication; several point to bodies of work rather than a single paper.

    Find out what is driving your nerve pain

    The free, five-question Nerve Damage Score takes about two minutes and tells you which terrain failure is most likely behind your symptoms.

    Get My Free Nerve Damage Score

    Or call or text (314) 886-5902.

    Related reading

  • The Regenerve Protocol for Peripheral Neuropathy: Beyond Managing the Pain

    If you live with peripheral neuropathy, you already know the standard script: a prescription for gabapentin or pregabalin, a suggestion to control your blood sugar, and a shrug when neither one gives your feet back to you. The Regenerve protocol starts from a different premise — that burning, tingling, and numbness are not the disease but the alarm, and that the goal of treatment is to repair the terrain the nerves live in, not simply to mute the signal they are sending. This article walks through the logic of that protocol, the science behind each stage, and an honest accounting of what is proven, what is emerging, and what remains investigational.

    Why symptom suppression alone falls short

    The medications most people are handed — the gabapentinoids (gabapentin, pregabalin) and certain antidepressants (duloxetine, amitriptyline) — work by dampening the transmission of pain signals in the nervous system. They are legitimate tools, and for many patients they take the edge off. But two facts are rarely explained at the pharmacy counter.

    First, the benefit is often partial. Across the neuropathic-pain literature, only a minority of patients achieve substantial (50% or greater) pain relief from any single oral agent, and many discontinue because of side effects like sedation, dizziness, weight gain, and cognitive fog. Second — and more fundamentally — none of these drugs touch the process that is damaging the nerve. They quiet the alarm while the fire keeps burning. That is why patients so often describe climbing to the maximum dose and still waking at 3 a.m. with their feet on fire.

    The Regenerve premise is that lasting change requires addressing why the nerve is failing, then giving it the conditions to recover.

    Metabolic sovereignty: treating the terrain, not just the nerve

    Dr. Padda uses the phrase “metabolic sovereignty” to describe the underlying philosophy: your nerves cannot heal in a hostile environment. A nerve fiber is one of the most metabolically demanding structures in the body. It must maintain an electrical gradient along its entire length, transport nutrients and mitochondria from the cell body out to the nerve endings, and constantly repair its insulating myelin. Starve it of oxygen, poison it with the byproducts of high blood sugar, or drain its energy supply, and it will misfire, retract, and eventually die back — starting at the longest, most distant fibers, which is why symptoms begin in the toes and feet.

    So before any regenerative step makes sense, the terrain has to be assessed and corrected: blood sugar and glycation, micronutrient status, circulation, inflammatory drivers, and mechanical contributors. This is the diagnostic backbone that a companion article — “The 11 Hidden Drivers Your Doctor Missed” — explores in depth. The protocol below assumes that this root-cause work is happening in parallel; the regenerative tools are not a substitute for it.

    Stage one: quiet the overfiring nerve

    When a damaged nerve becomes chronically hyperexcitable, it fires pain even in the absence of a real threat. One way to interrupt that is to “defunctionalize” the overactive pain fibers at the skin level using high-concentration capsaicin.

    The 8% capsaicin patch (marketed as Qutenza) is the most evidence-backed piece of this stage. It works on the TRPV1 receptor — the same receptor that makes chili peppers feel hot — which sits on the small pain-sensing C-fibers in the skin. A single controlled application overstimulates and then reversibly “switches off” those endings, reducing their pain signaling for weeks to months. This is not folk medicine: the U.S. FDA approved the 8% capsaicin patch for postherpetic neuralgia in 2009 and, after the pivotal STEP trial led by Dr. David Simpson, for painful diabetic peripheral neuropathy of the feet in 2020. In the controlled data, a single 30-minute treatment produced modest but statistically significant reductions in daily pain, with the main side effect being temporary application-site burning, and — importantly — no deterioration in patients’ ability to sense sharp, warm, cold, or vibration stimuli. A separate 52-week safety study (PACE) supported repeated treatment without functional or neurological harm.

    An honest caveat belongs here, because it is where marketing often overreaches: the established benefit of capsaicin is pain relief, not proven nerve regrowth. Whether repeated capsaicin treatment can help damaged nerve fibers actually regenerate is a genuine scientific question currently under formal investigation (including a randomized disease-modification trial out of Cambridge), not a settled fact. Regenerve uses capsaicin to create a window of reduced pain and reduced nociceptor overactivity — a window in which the repair-focused steps have room to work.

    Stage two: support structural repair with orthobiologics

    Once the fire is calmer and the terrain is being corrected, the protocol turns to helping the tissue rebuild. This is where orthobiologics enter — biological materials intended to deliver growth factors and signaling molecules to injured tissue. In the Regenerve protocol these include platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), both derived from the patient’s own blood or marrow.

    The rationale is grounded in real biology. Platelets are packed with growth factors — including nerve growth factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and platelet-derived growth factor — that orchestrate healing, angiogenesis (new blood-vessel formation), and, in laboratory and animal models, peripheral nerve regeneration. BMAC additionally supplies a mesenchymal cell population that can modulate inflammation.

    Here transparency is essential, and Regenerve’s material is careful about it: the use of PRP and BMAC for peripheral nerve repair is an emerging, largely investigational application. The strongest evidence to date comes from preclinical models and small clinical series, not large randomized trials, and these therapies are not FDA-approved specifically for peripheral neuropathy. Presented honestly, they are a mechanism-driven, patient-derived intervention with encouraging early signals and an incomplete evidence base — which is exactly why they belong in a physician-directed, individualized plan with realistic expectations, not a one-size-fits-all promise.

    Stage three: restore the cellular power plant

    Even a structurally intact nerve cannot function if its mitochondria — the energy generators inside each cell — are failing. Chronic hyperglycemia, toxins, and nutrient deficiencies all converge on mitochondrial dysfunction, and Dr. Michael Brownlee’s landmark work showed that overproduction of mitochondrial superoxide is a unifying mechanism behind the tissue damage of diabetes. Repairing the wiring without restoring the power supply leaves the job half done.

    The protocol therefore incorporates mitochondrial support. This ranges from well-established repletion of the cofactors nerves depend on — the B vitamins, alpha-lipoic acid, and CoQ10 among them — to more advanced, targeted agents. SS-31 (elamipretide) is a mitochondria-targeted peptide designed to stabilize cardiolipin in the inner mitochondrial membrane and improve energy production; it is a real and actively studied compound, but it remains investigational and is not an FDA-approved neuropathy treatment. As with the orthobiologics, the honest framing is that the mitochondrial-support layer combines proven nutritional science with newer, still-experimental tools, selected case by case.

    Why sequence matters

    The order is deliberate. Correcting the terrain first means the body is no longer actively re-injuring the nerve. Calming the overfiring pain fibers next creates a period of reduced pain and reduced nociceptor chaos. Delivering repair signals and restoring mitochondrial energy last gives the nerve both the instructions and the fuel to recover during that window. Reverse the order — try to “regenerate” a nerve that is still being starved and glycated every day — and you are building on sand.

    What to expect as a patient

    Peripheral nerves repair slowly, on the order of about a millimeter a day at best, so this is a months-long process measured in gradual change, not an overnight fix. A realistic plan begins with evaluation and diagnostics to map which drivers are active, sets expectations honestly, and adjusts over time based on response. Some patients experience meaningful improvement; results vary by individual and by how advanced the nerve loss is at the start. The earlier the terrain is corrected, the more nerve there is to save.

    Frequently asked questions

    Is the Regenerve protocol a cure for neuropathy?

    No responsible clinician promises a cure for nerve damage. The protocol aims to stop ongoing injury, reduce pain, and create conditions that support repair. Outcomes vary, and advanced nerve loss may only partially recover.

    Do I stop my gabapentin or other medications?

    Never stop a prescribed medication on your own. These drugs can be valuable for pain control while the underlying terrain is addressed; any changes are made only with your physician.

    Is capsaicin the same as the cream at the drugstore?

    No. The 8% patch is a prescription-strength, in-office treatment — roughly 100 times more concentrated than over-the-counter capsaicin creams — and is applied under medical supervision.

    Are PRP, BMAC, and SS-31 proven for neuropathy?

    They are mechanism-driven and, in the case of PRP/BMAC, derived from your own body, but their use in peripheral neuropathy is emerging and investigational. They are offered as part of an individualized, physician-directed plan, not as guaranteed therapies.

    Key takeaways

    • Standard drugs mute the pain signal but do not repair the nerve; partial relief and side effects are common.
    • The Regenerve protocol treats the terrain first, then calms overfiring nerves, then supports structural and mitochondrial repair.
    • The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet and provides real, if modest, pain relief; nerve-regrowth claims remain under investigation.
    • Orthobiologics (PRP, BMAC) and mitochondrial peptides (SS-31) are biologically rational but investigational for neuropathy, and belong in an individualized plan.
    • Nerve repair is slow; earlier intervention preserves more function.

    Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

    This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication or treatment without consulting your physician. Ready to start? Take the free Nerve Damage Score or call/text (314) 886-5902.

    References

    1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
    2. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
    3. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for neuropathic pain associated with diabetic peripheral neuropathy of the feet. 2020.
    4. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
    5. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
    6. Sánchez M, et al. Platelet-rich plasma and peripheral nerve regeneration (review of preclinical and early clinical evidence).
    7. Szeto HH. First-in-class cardiolipin-protective compound (SS-31/elamipretide) as a therapeutic agent for mitochondrial dysfunction. Br J Pharmacol. 2014.

    Note: References 6–7 point to real bodies of work but should be matched to specific, current citations at publication. PRP/BMAC and SS-31 applications to peripheral neuropathy are investigational.

    Find out what is driving your nerve pain

    The free, five-question Nerve Damage Score takes about two minutes and tells you which terrain failure is most likely behind your symptoms.

    Get My Free Nerve Damage Score

    Or call or text (314) 886-5902.

    Related reading